Taran Therapeutics
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
533 Airport Blvd Ste 400, Burlingame, Ca...Phone Number
(908) 672-9908Website
www.tarantherapeutics.comRevenue
<$5 MillionIndustry
About Taran Therapeutics
Taran Therapeutics Org Chart
Is Taran Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Taran Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Taran Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Taran Therapeutics recently announced quarterly report
Check if Taran Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Taran Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Taran Therapeutics launches new products
Taran Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Taran Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Taran Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Taran Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Taran Therapeutics.
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Taran Therapeutics
Taran Therapeutics is a privately-owned biotech company focused on developing late-stage clinical therapies for leukemia and cancer, particularly in the field of hematology/oncology and chronic inflammation. Their lead candidate, Lenzilumab (LENZ), is currently completing a Phase 2/3 trial for treatment-naive Chronic MyeloMonocytic Leukemia (CMML)... Read More